At the news
? BEARISHIMPACT 7/10 8-K filed Sep 15, 2026 at 08:57 ET
GT Biopharma entered into a securities purchase agreement to sell up to 41,778 shares of Series M 10% Convertible Preferred Stock and warrants for gross proceeds of up to $8,277,778 ($7,450,000 net after a 10% original issue discount). The offering includes a $30M greenshoe option and is highly dilutive, with a conversion/exercise price of $6.10 per share, subject to further price resets. The company also filed a Certificate of Designation for the preferred stock and a Registration Rights Agreement. This is a distressed financing by a micro-cap biotech with a $21M market cap, signaling acute capital needs and severe dilution risk for common shareholders.
- Company sold up to 41,778 shares of Series M 10% Convertible Preferred Stock for aggregate gross proceeds of up to $8,277,778 (net $7,450,000 after 10% OID).
- Investors receive common stock warrants for 100% of conversion shares, exercisable at $6.10 for 5 years.
- Greenshoe option allows investors to purchase up to an additional $33.3M stated value of preferred stock ($30M purchase price).
- Conversion price of $6.10 is subject to further downward adjustment via a price reset mechanism tied to Greenshoe exercises, with a floor of $1.282.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access